Published in Am J Pathol on May 01, 2002
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol (2004) 0.94
Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int (2010) 0.92
Guidelines for HER2 testing in the UK. J Clin Pathol (2004) 0.91
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol (2010) 0.86
Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol (2004) 0.84
Genotyping of phenotypically defined cells in neoplasia: enhanced immunoFISH via tyramide signal amplification (TSA) segregates immunophenotypically-defined cell populations for gated genotyping. J Mol Histol (2007) 0.77
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol (1997) 3.66
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene (1996) 3.33
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res (1994) 3.03
Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol (2000) 2.86
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol (1999) 2.48
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol (1993) 2.15
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol (1992) 2.10
Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer (1991) 1.85
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol (2001) 1.62
Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res (1989) 1.58
HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol (2000) 1.25
HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn (2000) 1.25
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol (2000) 1.15
HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol (2000) 1.13
Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu status in breast carcinoma. Mol Diagn (2000) 1.09
Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol (2001) 1.06
Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol (2000) 1.01
c-erbB-2 amplification in node-negative human breast cancer. Cancer Res (1989) 0.94
Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. J Mol Diagn (2000) 0.83
Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology (2000) 0.82
Detection of human papillomavirus in cervical carcinoma: comparison of peroxidase, Nanogold, and catalyzed reporter deposition (CARD)-Nanogold in situ hybridization. Mod Pathol (1999) 0.81
Clinical relevance of HPV 16/18 testing methods in cervical squamous cell carcinoma. Appl Immunohistochem Mol Morphol (2000) 0.81
Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci (2000) 0.80
Significance of c-erbB-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer. Cancer (1992) 0.78
The quality of Her-2/Neu predictive immunohistochemistry: something FISHy? Mod Pathol (2000) 0.77
BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet (2004) 6.85
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
Relevance of random biopsy at the transformation zone when colposcopy is negative. Obstet Gynecol (2014) 2.71
The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53
Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol (2005) 2.39
A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol (2007) 2.15
Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovis aries). Biol Reprod (2003) 2.14
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol (2008) 1.95
A linkage map for brown trout (Salmo trutta): chromosome homeologies and comparative genome organization with other salmonid fish. Genetics (2006) 1.89
Comparative genome analysis of the primary sex-determining locus in salmonid fishes. Genome Res (2003) 1.85
The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res (2005) 1.68
Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer (2006) 1.62
Laparoscopic anatrophic nephrolithotomy: feasibility study in a chronic porcine model. J Urol (2003) 1.58
Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol (2012) 1.57
Life history shapes gene expression in salmonids. Curr Biol (2006) 1.55
Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol (2008) 1.46
BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum (2012) 1.42
Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl Immunohistochem Mol Morphol (2003) 1.37
Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol (2007) 1.36
Analysis and management of resistance to chemotherapeutants in salmon lice, Lepeophtheirus salmonis (Copepoda: Caligidae). Pest Manag Sci (2002) 1.25
Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol (2005) 1.19
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn (2008) 1.17
Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer (2012) 1.12
Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol (2007) 1.10
The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol (2005) 1.05
Variation of monosomy 3 status within uveal melanoma. Arch Pathol Lab Med (2009) 1.04
Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma. Diagn Mol Pathol (2003) 1.04
Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol (2010) 1.03
Eccrine angiomatous hamartoma in a neurofibromatosis type-1 patient. Pathology (2002) 1.01
Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol (2004) 1.00
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 0.99
EST-based identification of genes expressed in the liver of adult Atlantic salmon (Salmo salar). Biochem Biophys Res Commun (2002) 0.99
Transfer and multiplex immunoblotting of a paraffin embedded tissue. Proteomics (2006) 0.98
Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer (2008) 0.98
The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer (2014) 0.96
Primary extraosseous ewing sarcoma of the kidney with level III inferior vena cava thrombus. Clin Genitourin Cancer (2009) 0.96
Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities. Obstet Gynecol (2007) 0.96
Identifying Lynch syndrome: we are all responsible. Dis Colon Rectum (2008) 0.95
Inhibiting CXCL12 blocks fibrocyte migration and differentiation and attenuates bronchiolitis obliterans in a murine heterotopic tracheal transplant model. J Thorac Cardiovasc Surg (2012) 0.93
Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol (2005) 0.93
Altered expression of connexin subtypes in mesial temporal lobe epilepsy in humans. J Neurosurg (2006) 0.91
Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum (2013) 0.91
Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck (2003) 0.91
Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. Gastrointest Endosc (2004) 0.89
The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms. Am J Surg Pathol (2008) 0.88
Oral and tympanic membrane temperatures are inaccurate to identify Fever in emergency department adults. West J Emerg Med (2011) 0.87
MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol (2006) 0.87
Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists. Am J Surg Pathol (2007) 0.87
Effect of intentional cryo-injury to the renal collecting system. J Urol (2003) 0.87
Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol (2004) 0.86
Epithelioid sarcoma: an immunohistochemical analysis evaluating the utility of cytokeratin 5/6 in distinguishing superficial epithelioid sarcoma from spindled squamous cell carcinoma. J Cutan Pathol (2003) 0.86
The specificity of interphase FISH translocation probes in formalin fixed paraffin embedded tissue sections is readily assessed using automated staining and scoring of tissue microarrays constructed from murine xenografts. J Mol Histol (2006) 0.86
The treatment of disabling intermittent claudication in patients with superficial femoral artery occlusive disease--decision analysis. J Vasc Surg (2007) 0.84
Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol (2004) 0.84
Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence. J Mol Diagn (2006) 0.84
Postmortem stability of RNA isolated from bovine reproductive tissues. Biochim Biophys Acta (2002) 0.84
Investigation of prolific sheep from UK and Ireland for evidence on origin of the mutations in BMP15 (FecX(G), FecX(B)) and GDF9 (FecG(H)) in Belclare and Cambridge sheep. PLoS One (2013) 0.84
Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. Int J Cancer (2012) 0.82
Primary intravascular synovial sarcoma: a disease of young adult women? Report of a case diagnosed by aspiration biopsy and review of the literature. Diagn Cytopathol (2006) 0.82
Prediction of adenocarcinoma in esophagectomy specimens based upon analysis of preresection biopsies of Barrett esophagus with at least high-grade dysplasia: a comparison of 2 systems. Am J Surg Pathol (2012) 0.81
Suprabasal overexpression of beta-1 integrin is induced by bovine papillomavirus type 1. Virology (2006) 0.81
The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol (2005) 0.80
Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med (2003) 0.80
A treatment for allergic rhinitis: a view on the role of levocetirizine. Curr Med Res Opin (2005) 0.80
Familial colorectal cancer type X: polyp burden and cancer risk stratification via a family history score. ANZ J Surg (2012) 0.80
A phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Res Treat (2003) 0.80
The utility of FOXO1 fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded specimens in the diagnosis of alveolar rhabdomyosarcoma. Diagn Mol Pathol (2009) 0.79
Analysis of gene expression in the bovine corpus luteum through generation and characterisation of 960 ESTs. Biochim Biophys Acta (2004) 0.79
Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol (2002) 0.79
Laparoscopic ureterocalicostomy: a feasibility study. J Urol (2003) 0.78
Endocervical curettage. Does it contribute to the management of patients with abnormal cervical cytology? J Reprod Med (2004) 0.78
Analysis of gene expression in non-regressed and regressed bovine corpus luteum tissue using a customized ovarian cDNA array. Theriogenology (2005) 0.78
Array-based comparative genomic hybridization in ulcerative colitis neoplasia: single non-dysplastic biopsies distinguish progressors from non-progressors. Mod Pathol (2010) 0.78
A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry. Hum Pathol (2013) 0.77
Cervical stromal invasion predicting survival in endometrial cancer. Obstet Gynecol (2010) 0.76
Cell surface expression of TNFRI in tumor necrosis factor receptor-associated periodic syndrome: comment on the article by Nedjai et al. Arthritis Rheum (2008) 0.75
Nuclear, intradiscal hemangioma. Pain Pract (2008) 0.75
Chromosome 1p allelic loss by fluorescence in situ hybridization is not observed in dysembryoplastic neuroepithelial tumors. Am J Clin Pathol (2002) 0.75
Performance of an Human Papillomavirus Test in Samples From Women With Histopathologically Confirmed Invasive Cervical Cancer. J Low Genit Tract Dis (2016) 0.75
Performance of an Human Papillomavirus Test in Samples From Women With Histolopathologically Confirmed Invasive Cervical Cancer. J Low Genit Tract Dis (2016) 0.75